PTHS Stock Forecast: Pelthos Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Pelthos Therapeutics, Inc. is $40. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 37 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Pelthos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (69): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PTHS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PTHS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | Lake Street | Maintains | Buy | — |
| 14 Aug 2026 | Oppenheimer | Maintains | Outperform | — |
| 15 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 1 Apr 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 20 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 19 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Feb 2026 | Piper Sandler | Initiates | Overweight | — |
| 26 Feb 2026 | Roth Capital | Maintains | Buy | — |
| 26 Jan 2026 | Oppenheimer | Maintains | Outperform | — |
| 3 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 3 Dec 2025 | Lake Street | Initiates | Buy | — |
| 25 Nov 2025 | Roth Capital | Initiates | Buy | — |
| 14 Nov 2025 | Oppenheimer | Reiterates | Outperform | — |
| 2 Sept 2025 | Oppenheimer | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PTHS.
This page is one stock. Monday covers all of them.
PTHS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PTHS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Pelthos Therapeutics, Inc. returned −78.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PTHS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.5×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 79% of US stocks
- Revenue growth (YoY)
- 107.9%
- Earnings growth (YoY)
- —
- Gross margin
- 17.8%
- Operating margin
- −98.7%
- Net margin
- —
Higher than 93% of US stocks
Higher than 18% of US stocks
Higher than 14% of US stocks
- Return on equity
- —
- Return on assets
- −24.8%
- Dividend yield
- —
Higher than 17% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pelthos Therapeutics, Inc. has a market value of $25.1M and an enterprise value of $75.7M.
Revenue in the twelve months to 30 June 2026: $43.3M.
Net income over the same four quarters: −$86.4M, a −199.5% net margin.
Diluted earnings per share, trailing twelve months: −$21.88.
Free cash flow in the twelve months to 30 June 2026: −$50.5M.
Pelthos Therapeutics, Inc. employs 92 people — $471K of revenue per employee.
Data provided by Twelve Data
PTHS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PTHS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Pelthos Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PTHS
What is the PTHS stock price forecast for 2026-2027?
The median 12-month analyst price target for Pelthos Therapeutics, Inc. is $40, with estimates ranging from $21 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PTHS stock a buy right now?
Of the 7 analysts covering Pelthos Therapeutics, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pelthos Therapeutics, Inc. 37 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PTHS?
As at 21 Nov 2026, Pelthos Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (69 of 100).
Will PTHS stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $40, and Ticker Nerd's factor model ranks Pelthos Therapeutics, Inc. 37 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PTHS stock forecast for 2030?
No analyst covering Pelthos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTHS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $60 over the next 12 months.
How has PTHS stock performed over the past year?
Pelthos Therapeutics, Inc. returned -78.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Pelthos Therapeutics, Inc. do?
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The company’s current portfolio centers on dermatology and cutaneous infectious diseases, led by ZELSUVMI® (berdazimer) topical gel for molluscum contagiosum, a prescription treatment designed for use at home by patients, parents, and caregivers.
About Pelthos Therapeutics, Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The company’s current portfolio centers on dermatology and cutaneous infectious diseases, led by ZELSUVMI® (berdazimer) topical gel for molluscum contagiosum, a prescription treatment designed for use at home by patients, parents, and caregivers. Pelthos Therapeutics also markets XEPI® (ozenoxacin) Cream for impetigo and XEGLYZE® (abametapir) for head lice, giving it a commercial presence across several topical treatments used in everyday outpatient care. In addition, the company works with a proprietary nitric oxide-based technology platform, Nitricil, which supports its product development and commercialization efforts. Based in Durham, North Carolina, Pelthos Therapeutics operates as a commercial-stage specialty biotech company serving dermatology and infectious disease markets.
CEO Mr. Scott M. Plesha · 92 employees · United States · https://pelthos.com